EUVIMEDEUVIMED entdecken
Open Access

ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma

Isabel Arrillaga-Romany iD, Sharon L Gardner, Yazmin Odia iD, Dolly Aguilera iD, Joshua E Allen iD, Tracy Batchelor iD, Nicholas Butowski iD, Clark Chen iD, Timothy Cloughesy iD, Andrew Cluster iD, John de Groot iD, Karan S Dixit und 18 weitere

Journal of Clinical Oncology · 01.05.2024 · 42 (13) · 1542-1552

DOI: 10.1200/jco.23.01134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.05.2024. Verfasst von Isabel Arrillaga-Romany und 29 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Mutation, Histones. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Histone 3 (H3) K27M–mutant diffuse midline glioma (DMG) has a dismal prognosis with no established effective therapy beyond radiation. This integrated analysis evaluated single-agent ONC201 (dordaviprone), a first-in-class imipridone, in recurrent H3 K27M–mutant DMG. METHODS Fifty patients (pediatric, n = 4; adult, n = 46) with recurrent H3 K27M–mutant DMG who received oral ONC201 monotherapy in four clinical trials or one expanded access protocol were included. Eligible patients had measurable disease by Response Assessment in Neuro-Oncology (RANO) high-grade glioma (HGG) criteria and performance score (PS) ≥60 and were ≥90 days from radiation; pontine and spinal tumors were ineligible. The primary end point was overall response rate (ORR) by RANO-HGG criteria. Secondary end points included duration of response (DOR), time to response (TTR), corticosteroid response, PS response, and ORR by RANO low-grade glioma (LGG) criteria. Radiographic end points were assessed by dual-reader, blinded independent central review. RESULTS The ORR (RANO-HGG) was 20.0% (95% CI, 10.0 to 33.7). The median TTR was 8.3 months (range, 1.9-15.9); the median DOR was 11.2 months (95% CI, 3.8 to not reached). The ORR by combined RANO-HGG/LGG criteria was 30.0% (95% CI, 17.9 to 44.6). A ≥50% corticosteroid dose reduction occurred in 7 of 15 evaluable patients (46.7% [95% CI, 21.3 to 73.4]); PS improvement occurred in 6 of 34 evaluable patients (20.6% [95% CI, 8.7 to 37.9]). Grade 3 treatment-related treatment-emergent adverse events (TR-TEAEs) occurred in 20.0% of patients; the most common was fatigue (n = 5; 10%); no grade 4 TR-TEAEs, deaths, or discontinuations occurred. CONCLUSION ONC201 monotherapy was well tolerated and exhibited durable and clinically meaningful efficacy in recurrent H3 K27M–mutant DMG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsMutationHistonesHumansAdultFemaleMaleAdolescentMiddle AgedYoung AdultChildAgedNeoplasm Recurrence, LocalChild, PreschoolPyrimidinesPyridones

Substanzen

HistonesPyrimidinesPyridones

Autor:innen und Institutionen

  • Massachusetts General Hospital, Boston, MA.
  • New York University, Grossman School of Medicine, New York, NY.
  • Miami Cancer Institute, part of Baptist Health South Florida, Miami, FL.
  • Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA.
  • Chimerix, Inc, Durham, NC.
  • Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.

ORCID-Profile: Isabel Arrillaga-Romany, Yazmin Odia, Dolly Aguilera, Joshua E Allen, Tracy Batchelor, Nicholas Butowski, Clark Chen, Timothy Cloughesy, Andrew Cluster, John de Groot, Jerome J Graber, Rebecca A Harrison, Lindsay B Kilburn, Sylvia C Kurz, Guangrong Lu, Minesh Mehta, Phioanh Leia Nghiemphu, Nicole Shonka, Ashley Sumrall, Rohinton S Tarapore, Lynne Taylor, Patrick Y Wen

Förderung

  • NCI NIH HHS

Zitieren

APA

Arrillaga-Romany, I., Gardner, S. L., Odia, Y., Aguilera, D., Allen, J. E., Batchelor, T., Butowski, N., Chen, C., Cloughesy, T., Cluster, A., de Groot, J., Dixit, K. S., Graber, J. J., Haggiagi, A. M., Harrison, R. A., Kheradpour, A., Kilburn, L. B., Kurz, S. C., Lu, G., …, & Wen, P. Y. (2024). ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal of Clinical Oncology, 42(13), 1542-1552. https://doi.org/10.1200/jco.23.01134

Vancouver

Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, et al. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal of Clinical Oncology. 2024;42(13):1542-1552. doi:10.1200/jco.23.01134

BibTeX
@article{ArrillagaRomany2024,
  author = {Arrillaga-Romany, Isabel and Gardner, Sharon L and Odia, Yazmin and Aguilera, Dolly and Allen, Joshua E and Batchelor, Tracy and Butowski, Nicholas and Chen, Clark and Cloughesy, Timothy and Cluster, Andrew and de Groot, John and Dixit, Karan S and Graber, Jerome J and Haggiagi, Aya M and Harrison, Rebecca A and Kheradpour, Albert and Kilburn, Lindsay B and Kurz, Sylvia C and Lu, Guangrong and MacDonald, Tobey J and Mehta, Minesh and Melemed, Allen S and Nghiemphu, Phioanh Leia and Ramage, Samuel C and Shonka, Nicole and Sumrall, Ashley and Tarapore, Rohinton S and Taylor, Lynne and Umemura, Yoshie and Wen, Patrick Y},
  title = {ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {13},
  pages = {1542--1552},
  doi = {10.1200/jco.23.01134}
}
Kostenlos starten →